Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
Status:
Completed
Trial end date:
2021-01-05
Target enrollment:
Participant gender:
Summary
This randomized phase Ib trial studies the side effects and best dose of naproxen in
preventing deoxyribonucleic acid (DNA) mismatch repair deficient colorectal cancer in
patients with Lynch syndrome. Chemoprevention is the use of certain drugs to keep cancer from
forming. The use of naproxen may keep cancer from forming in patients with Lynch syndrome.